619 material Form 8-K filings that 507 companies we cover made with the SEC in December 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
The closed-end fund agreed to issue 4,000,000 Series A Mandatorily Redeemable Preferred Shares due December 18, 2030, at a $25.00 liquidation preference, raising gross proceeds of $100 million in a private placement under Rule 506(c). The fund also adopted a Statement of Preferences setting the rights of these shares. The filing describes new fixed-term preferred financing rather than a change in the fund's common shares.
Issuance of 4,000,000 Series A MRP Shares with a $25.00 liquidation preference each
Gross proceeds from the sale of $100 million
Shares are due December 18, 2030, and were sold under Rule 506(c) private placement exemption
Statement of Preferences adopted December 18, 2025, filed as Exhibit 3.1
On December 12, 2025, Karbon Capital Partners Corp., a blank check company with no operations, completed its initial public offering of 34,500,000 units at $10.00 each, generating $345 million in gross proceeds. The full $345 million was placed in a trust account with Continental Stock Transfer & Trust Company as trustee, and the company cannot withdraw the principal except for limited tax and dissolution expenses until a business combination or redemption occurs. For shareholders, the capital is held in trust with no target company yet selected, and the company must complete a business combination within 24 months (or 27 months if a letter of intent is signed) or redeem public shares.
IPO of 34,500,000 units at $10.00 per unit closed on December 12, 2025, including 4,500,000 units from the full exercise of the underwriters' over-allotment option.
Sponsor Karbon Capital Partners Core Holdings, LLC bought 890,000 private placement units at $10.00 each, generating $8.9 million.
$345 million placed in trust account; the company has not selected any business combination target.
Combination period is 24 months, or 27 months if a letter of intent is entered; transaction costs totaled $20,186,929, including a $12,075,000 deferred underwriting fee.
Zoetis completed a private offering of $2.0 billion in 0.25% convertible senior notes due June 15, 2029, including a $250 million option that the initial purchasers exercised in full. The company estimates net proceeds of about $1,969.6 million and plans to use most of them to repurchase its common stock under its existing $6 billion repurchase program, with the remaining buybacks expected to be completed by the first quarter of 2026.
Notes total $2.0 billion principal, with a 0.25% annual interest rate payable semiannually starting June 15, 2026
Estimated net proceeds of $1,969.6 million: $186.6 million for capped call transactions, $248.0 million to buy about 2.1 million shares, and $1,535.0 million for further repurchases
Initial conversion price is about $148.20 per share, a 22.5% premium to the December 15, 2025 NYSE closing price
Notes mature June 15, 2029 and are senior unsecured obligations of Zoetis
Arcus Biosciences entered into a First Amendment to its August 27, 2024 Loan and Security Agreement with Hercules Capital and the lenders, which governs the remaining $150.0 million of term loan commitments. The amendment ties the timing of future borrowing to set dates and to clinical and regulatory milestones, extends the maturity date to September 1, 2030, and adds performance covenants that apply if term loan advances exceed $200.0 million.
Maturity date extended to September 1, 2030, with no further extension right.
Remaining $150.0 million of term loan commitments: $25.0 million available through March 15, 2026, $25.0 million through September 15, 2026, and up to $50.0 million each after a Phase 3 Clinical Milestone and after FDA approval (Milestone I
Covenants apply if advances exceed $200.0 million, starting with quarterly statements three quarters after Milestone I: market capitalization of at least $1.5 billion plus Qualified Cash of at least 50.0% of secured obligations, or Qualifie
Crane Harbor Acquisition Corp. II, a blank check company, closed its initial public offering of 34,500,000 units at $10.00 per unit on December 17, 2025, for gross proceeds of $345 million, including the over-allotment option exercised in full. The filing says $345 million of IPO and private placement proceeds was placed in a trust account for public shareholders, to be released only after an initial business combination or redemption rights are triggered, with a 24-month deadline to complete a deal.
34,500,000 units sold at $10.00 each, including 4,500,000 units from the over-allotment option exercised December 16, 2025
Private placement of 900,000 units for $9 million, with the sponsor buying 600,000 units
$345 million placed in trust; funds generally not released until a business combination or redemption if none is completed within 24 months
Seven directors appointed December 15, 2025, and Jeffrey F. Brotman resigned from the board
Spire and its subsidiaries signed a First Amendment to their existing loan agreement with Wells Fargo as administrative agent. The amendment adds Spire Tennessee as a borrower and extends the final maturity date to October 11, 2030. The filing does not disclose the size of the credit facility or any new borrowing amount.
Amendment dated December 18, 2025, amends the Second Amended and Restated Loan Agreement dated October 11, 2024
Spire Tennessee Inc. joins as a borrower, subject to the loan agreement terms
Final maturity date extended to October 11, 2030
Spire, Spire Missouri and Spire Alabama paid arrangement and extension fees under a Fee Letter dated December 4, 2025
LKQ amended its credit agreement on December 17, 2025, extending the revolving credit maturity date to December 17, 2030. It also extended the maturity of its CAD term loan to March 17, 2029, while the term loan under the main credit agreement remains due January 5, 2027. The filing describes the changes as administrative and does not state any new borrowing amount or change in pricing.
Revolving Credit Maturity Date extended to December 17, 2030 under Amendment No. 5
CAD Note Maturity Date extended to March 17, 2029 under CAD Note Amendment No. 4
Term Loan Maturity Date unchanged at January 5, 2027
Earlier amendments dated November 26, 2025 were filed as exhibits, covering a change to the definition of "UK Joint Venture"
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.